AdvanCell’s $315 million radiopharma Series D is part of a broader pattern of sustained funding for asset-heavy, execution-focused biotech. In parallel, multiple AI-driven discovery and platform companies are capturing large rounds or building late-stage capabilities, with investors increasingly demanding manufacturing readiness and demonstrable target engagement. The funding mix also shows that diagnostics and CGT manufacturing automation are receiving capital when they can translate into faster turnaround, quality improvements, or scalable production processes. Taken together, these moves reflect a market that is rewarding concrete development plans and regulatory-forward execution rather than early-stage storytelling alone. As a result, capital availability is clustering around programs with clear clinical endpoints, manufacturability pathways, and commercialization strategies.